REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Back to transformations
BeforeBefore
AfterAfter
by Finley Muller 262 · 12 days ago

Combined peptide stack for overall wellness. Used BPC-157, Ipamorelin, and GHK-Cu together. Comprehensive progress photos and metrics.

BPC-157IpamorelinGHK-Cu
2025-11-24 → 2026-04-1119 weeks

Comments (2)

Beau Tanaka 393·4 days ago

Would love to see a 6-month follow-up to see if the gains are maintained long-term.

Beau Patel 93·3 days ago

Great documentation of your progress. This kind of detailed tracking helps the whole community learn.

Sign in to comment.